| GC34726-50mg |
|
916493-82-8 |
PROTAC BET-binding moiety 2
|
0 |
C20H17ClN4O4S |
|
|
|
| GC34726-10mg |
|
916493-82-8 |
PROTAC BET-binding moiety 2
|
0 |
C20H17ClN4O4S |
|
|
|
| GC34726-5mg |
|
916493-82-8 |
PROTAC BET-binding moiety 2
|
0 |
C20H17ClN4O4S |
|
|
|
| GC34726-10mM (in 1mL DMSO) |
|
916493-82-8 |
PROTAC BET-binding moiety 2
|
0 |
C20H17ClN4O4S |
|
|
|
| GC34725-50mg |
|
2093387-77-8 |
PROTAC BET-binding moiety 1
|
0 |
C25H25N7O4 |
|
|
|
| GC34725-10mg |
|
2093387-77-8 |
PROTAC BET-binding moiety 1
|
0 |
C25H25N7O4 |
|
|
|
| GC34725-5mg |
|
2093387-77-8 |
PROTAC BET-binding moiety 1
|
0 |
C25H25N7O4 |
|
|
|
| GC34724-100mg |
|
12071-83-9 |
|
0 |
C5H8N2S4Zn |
|
|
|
| GC34712-5mg |
|
— |
|
0 |
C20H20N4O4 |
|
|
|
| GC34712-10mM (in 1mL DMSO) |
|
— |
|
0 |
C20H20N4O4 |
|
|
|
| GC34710-5mg |
|
1892576-58-7 |
|
0 |
C26H26F3N5O2 |
|
|
|
| GC34709-5mg |
|
1609465-89-5 |
|
0 |
C22H20F2N6O2 |
|
|
|
| GC34708-50mg |
|
2040295-03-0 |
Pexidartinib hydrochloride
|
0 |
C20H16Cl2F3N5 |
|
|
|
| GC34708-10mg |
|
2040295-03-0 |
Pexidartinib hydrochloride
|
0 |
C20H16Cl2F3N5 |
|
|
|
| GC34708-10mM (in 1mL DMSO) |
|
2040295-03-0 |
Pexidartinib hydrochloride
|
0 |
C20H16Cl2F3N5 |
|
|
|
| GC34705-25mg |
|
1426833-08-0 |
|
0 |
C15H10ClN5 |
|
|
|
| GC34705-10mg |
|
1426833-08-0 |
|
0 |
C15H10ClN5 |
|
|
|
| GC34705-5mg |
|
1426833-08-0 |
|
0 |
C15H10ClN5 |
|
|
|
| GC34703-5mg |
|
77422-99-2 |
|
0 |
C19H14N4O4 |
|
|
|
| GC34701-5mg |
|
139954-00-0 |
|
0 |
C22H30O4 |
|
|
|
